46 filings
8-K
XERS
Xeris Pharmaceuticals Inc
5 Oct 21
Completion of Acquisition or Disposition of Assets
4:20pm
8-K
XERS
Xeris Pharmaceuticals Inc
5 Oct 21
Entry into a Material Definitive Agreement
4:15pm
8-K
XERS
Xeris Pharmaceuticals Inc
14 Sep 21
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
5:07pm
8-K
XERS
Xeris Pharmaceuticals Inc
5 Aug 21
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
7:36am
8-K
XERS
Xeris Pharmaceuticals Inc
30 Jul 21
Xeris Pharmaceuticals, Inc. Provides Announcement under the Irish Takeover Rules for Relevant Securities in Issue
7:57am
8-K
1lkxvn7fencivqwuz83
29 Jul 21
Xeris Pharmaceuticals Announces Executive Changes As Part of Its Strategy to Position the Company for Long-term Commercial Success
12:00am
8-K
ui4xxprwhpmrueaz
19 Jul 21
Xeris Pharmaceuticals Enters into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® In Europe
8:51am
8-K
oylkt
8 Jun 21
Submission of Matters to a Vote of Security Holders
4:52pm
8-K
ctg1nkudrq9
24 May 21
This Announcement Is Being Made Pursuant to Rule 2.5 of the Irish Takeover Rules
7:11am
8-K
tys5nx6 tffmlc
13 May 21
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
8:08am
8-K
0jy39lqoei xh1fd
6 May 21
Xeris Pharmaceuticals Announces Extension of the Interest-only Period of Its Debt Facility with Oxford Finance and Silicon Valley Bank
4:04pm
8-K
rhfyx347s2jyjh
11 Mar 21
Xeris Pharmaceuticals Announces Pricing of $27.0 Million
7:09am
8-K
xxriakjxl q86g
9 Mar 21
Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights
7:07am
8-K
uwk3zfhqp1ua4x
17 Dec 20
Departure of Directors or Certain Officers
4:05pm
8-K
u0tm40fe r49w6
14 Dec 20
Other Events
5:01pm
8-K
y7fxo7ixubyr9yoz y8t
16 Nov 20
Unregistered Sales of Equity Securities
7:26am
8-K
6va5hb z0oz
9 Nov 20
Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
7:04am
8-K
uj8 sgn1r
8 Oct 20
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
16dbz2oiq1i3jfgl
20 Aug 20
Xeris Pharmaceuticals Appoints John Shannon President and Chief Operating Officer
4:18pm
8-K
2zgd12
10 Aug 20
Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights
7:08am